Table 3.
Biological therapies for sHLH/MAS in clinical trials.
| Target | Drug | Type of Drug | Preclinical | Phase I | Phase II | Phase III | Identifier | Ref. |
|---|---|---|---|---|---|---|---|---|
| JAK 1/2 | Ruxolitinib | JAK 1/2 inhibitors |  |
NCT05137496 | NA | |||
| Methylprednisolone | ||||||||
| IL-1 | Anakinra | IL-1R antagonists |  |
NCT02780583 | 116 | |||
| Methylprednisolone | ||||||||
| IL-2 | rhIL-2 | Recombinant hIL-2 protein |  |
NCT02569463 | NA | |||
| IFN-γ | Emapalumab | Anti-IFNγ mAb |  |
NCT03311854 | NA | |||
| IL-1 | Anakinra | IL-1R antagonist |  |
NCT04339712 | NA | |||
| IL-6 | Tocilizumab | Anti-IL-6 mAb | ||||||
| IL-18 | Tadekinig alfa | IL-18BP |  |
NCT03512314 | NA | |||
| IL-2R | Rituximab | Anti-CD20 mAb |  |
NCT05384743 | NA | |||
| IL-1 | Anakinra | IL-1R antagonist |  |
NCT03332225 | 117 | |||
| IFNγ-1β | Imukin | Recombinant hIFNγ-1b protein | ||||||